Cartesian Therapeutics (RNAC) Accumulated Depreciation (2015 - 2016)
Cartesian Therapeutics (RNAC) posted quarterly Accumulated Depreciation of $3.3 million for Q2 2016, up 13.32% quarter-over-quarter from $2.9 million in Q4 2015.
Cartesian Therapeutics (RNAC) Accumulated Depreciation (2015 - 2016) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Accumulated Depreciation for 2 consecutive years, with $3.3 million the latest figure, recorded in Q2 2016.
- In Q2 2016, Accumulated Depreciation changed N/A year-over-year to $3.3 million; the TTM figure through Jun 2016 stood at $3.3 million (changed N/A YoY), while the FY2015 annual figure was $2.9 million, changed N/A from the prior year.
- Accumulated Depreciation improved to $3.3 million in Q2 2016 per RNAC's latest filing, from $2.9 million in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $3.3 million in Q2 2016 and bottomed at $2.9 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 3.32 Mn |
| Dec 31, 2015 | 2.93 Mn |